Praxis Dr. Jürgen Schmidt
- Address
- Pfarrgasse 57, 65239 Hochheim Am Main, Germany
Immune System Diseases
Praxis Dr. Jürgen Schmidt conducts research on Herpes Zoster vaccination, assessing long‑term efficacy, safety, and the persistence of the immune response in older adults.
- Evaluation of vaccine efficacy in preventing shingles
- Assessment of safety profiles for senior populations
- Study of immune response durability over time
- Exploration of preventive strategies for viral‑induced immune disorders
The site’s expertise in immunology supports the development of vaccines that protect against immune‑mediated viral diseases.
Respiratory Tract Diseases
Research at the center includes an Respiratory Syncytial Virus vaccine program that measures the humoral immune response after single revaccination doses given in seasonal windows for adults aged 60 and above.
- Timing of revaccination in pre‑season periods
- Safety monitoring in elderly participants
- Analysis of antibody levels post‑vaccination
- Impact of seasonal administration on disease prevention
These studies aim to reduce the burden of RSV‑related respiratory illness in the senior community.
Virus Diseases
The site advances viral vaccine research by evaluating both shingles and RSV immunizations, focusing on overall effectiveness and long‑term protection in adult populations.
- Cross‑protective benefits of viral vaccines
- Durability of immune responses across different viruses
- Adult immunization strategies for viral infections
- Potential public‑health impact of widespread vaccine use
Collaborative efforts with European health agencies enhance the translation of trial findings into broader preventive health measures.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GlaxoSmithKline Biologicals2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Praxis Dr. Jürgen Schmidt
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Immunogenicity and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ Following Revaccination Schedules in a Phase 3b Extension Study | GlaxoSmithKline Biologicals | Phase III | Not Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Recombinant Varicella Zoster Virus Glycoprotein E | 1 | Unknown | 2022-08-08 | 2022-08-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.